Table 2. Summary of patient cohort.
Comparison of natural history (NH) cohort with chemotherapy (CT) cohort. 1Performance score–performance score using Zubrod scale, 2OS–overall survival, 3MFS–metastatic-free survival, 4response to CT–response to chemotherapy according to RECIST criteria.
| NH cohort | CT cohort | ||
|---|---|---|---|
| N = 17 | N = 25 | ||
| Age | 67(55–78) | 63 (47–76) | |
| Sex | Female | 5 (30%) | 5 (20%) |
| Male | 12 (70%) | 20 (80%) | |
| Performance score1 | 0 | 5 (30%) | 1 (4%) |
| 1 | 7 (40%) | 22 (88%) | |
| 2 | 5 (30%) | 2 (8%) | |
| Stage | IIB | 1 (6%) | 0 (0%) |
| IIIA | 1 (6%) | 12 (48%) | |
| IIIB | 8 (47%) | 8 (32%) | |
| IV | 7 (40%) | 5 (20%) | |
| T | 1 | 0 (0%) | 1 (4%) |
| 2 | 2 (12%) | 7 (28%) | |
| 3 | 4 (24%) | 7 (28%) | |
| 4 | 11 (64%) | 8 (32%) | |
| x | 0 (0%) | 2 (8%) | |
| N | 0 | 3 (18%) | 1 (4%) |
| 1 | 1 (6%) | 2 (8%) | |
| 2 | 8 (47%) | 12 (48%) | |
| 3 | 4 (23%) | 9 (36%) | |
| x | 1 (6%) | 1 (4%) | |
| M | 0 | 10 (60%) | 20 (80%) |
| 1 | 7 (40%) | 5 (20%) | |
| Subtype | squamous | 14 (82%) | 16 (64%) |
| adenocarcinoma | 2 (12%) | 5 (20%) | |
| other | 1 (6%) | 4 (16%) | |
| OS2 | 7 (1–27) | 12 (1–81) | |
| MFS3 | 4 (0–27) | 7 (0–42) | |
| Chemotherapeutic drugs | cisplatin+ vinorelbine | 22 (88%) | |
| cisplatin+gemicitabine | 3 (12%) | ||
| Response to CT4 | complete response | 1(4%) | |
| partial response | 5 (20%) | ||
| stable disease | 5 (20%) | ||
| progressive disease | 8(32%) | ||
| undetermined | 6 (24%) |